KANTOFF AARON has filed 17 insider transactions across 2 companies since June 2024.
Most recent transaction: a option exercise of 3166 shares of Avalo Therapeutics, Inc. ($AVTX) on March 28, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 28, 2026 | Avalo Therapeutics, Inc. | $AVTX | KANTOFF AARON | Not found | M | Restricted Stock Units | 3166 | $0.00 | 3,167.0000 | 18,133,968 | 49.99% | 0.02% |
| March 28, 2026 | Avalo Therapeutics, Inc. | $AVTX | KANTOFF AARON | Not found | M | Common Stock | 3166 | $0.00 | 6,333.0000 | 18,133,968 | 99.97% | 0.02% |
| Oct. 28, 2025 | Tourmaline Bio, Inc. | $TRML | KANTOFF AARON | Not found | D | Employee Stock Option (Right to Buy) | 16800 | $0.00 | 0.0000 | 25,755,000 | 100.00% | 0.07% |
| Oct. 28, 2025 | Tourmaline Bio, Inc. | $TRML | KANTOFF AARON | Not found | D | Employee Stock Option (Right to Buy) | 10000 | $0.00 | 0.0000 | 25,755,000 | 100.00% | 0.04% |
| Oct. 28, 2025 | Tourmaline Bio, Inc. | $TRML | KANTOFF AARON | Not found | U | Common Stock | 88281 | $0.00 | 0.0000 | 25,755,000 | 100.00% | 0.34% |
| Oct. 24, 2025 | Tourmaline Bio, Inc. | $TRML | KANTOFF AARON | Not found | G | Common Stock | 5000 | $0.00 | 88,281.0000 | 25,755,000 | 5.36% | 0.02% |
| Sept. 5, 2025 | Tourmaline Bio, Inc. | $TRML | KANTOFF AARON | Not found | M | Common Stock | 10000 | $9.46 | 93,281.0000 | 25,755,000 | 12.01% | 0.04% |
| Sept. 5, 2025 | Tourmaline Bio, Inc. | $TRML | KANTOFF AARON | Not found | M | Common Stock | 37890 | $0.13 | 83,281.0000 | 25,755,000 | 83.47% | 0.15% |
| Sept. 5, 2025 | Tourmaline Bio, Inc. | $TRML | KANTOFF AARON | Not found | M | Stock Option (Right to Buy) | 37890 | $0.00 | 0.0000 | 25,755,000 | 100.00% | 0.15% |
| Sept. 5, 2025 | Tourmaline Bio, Inc. | $TRML | KANTOFF AARON | Not found | M | Stock Option (Right to Buy) | 10000 | $0.00 | 0.0000 | 25,755,000 | 100.00% | 0.04% |
| June 17, 2025 | Avalo Therapeutics, Inc. | $AVTX | KANTOFF AARON | Director | A | Stock Option (Right to Buy) | 20100 | $0.00 | 20,100.0000 | 10,671,934 | 9999.99% | 0.19% |
| June 4, 2025 | Tourmaline Bio, Inc. | $TRML | KANTOFF AARON | Director | A | Stock Option (Right to Buy) | 16800 | $0.00 | 16,800.0000 | 25,348,000 | 9999.99% | 0.07% |
| March 28, 2025 | Avalo Therapeutics, Inc. | $AVTX | KANTOFF AARON | Director | M | Restricted Stock Units | 3167 | $0.00 | 6,333.0000 | 10,671,934 | 33.34% | 0.03% |
| March 28, 2025 | Avalo Therapeutics, Inc. | $AVTX | KANTOFF AARON | Director | M | Common Stock | 3167 | $0.00 | 3,167.0000 | 10,671,934 | 9999.99% | 0.03% |
| Aug. 13, 2024 | Avalo Therapeutics, Inc. | $AVTX | KANTOFF AARON | Director | A | Restricted Stock Units | 9500 | $0.00 | 9,500.0000 | 0 | 9999.99% | 0.00% |
| Aug. 13, 2024 | Avalo Therapeutics, Inc. | $AVTX | KANTOFF AARON | Director | A | Stock Option (Right to Buy) | 24600 | $0.00 | 24,600.0000 | 0 | 9999.99% | 0.00% |
| June 5, 2024 | Tourmaline Bio, Inc. | $TRML | KANTOFF AARON | Director | A | Stock Option (Right to Buy) | 10000 | $0.00 | 10,000.0000 | 4,747,000 | 9999.99% | 0.21% |